Tu metaanaliza 13 badań nad iwermektyna, opublikowana kilku dni temu - lek zmniejszył śmiertelność, a stosowany profilaktycznie w 86% zapobiegł zakażeniu.

"Ivermectin for prevention and treatment of COVID-19 infection: a systematic review and meta-analysis"

"Meta-analysis of 13 trials found ivermectin reduced risk of death compared with no ivermectin (average Risk Ratio 0.32, 95% confidence interval (CI) 0.14 to 0.72; n=1892; I2=57%; low to moderate-certainty evidence. Low certainty evidence found ivermectin prophylaxis reduced covid-19 infection by an average 86% (95% CI 79% to 91%). Secondary outcomes provided very-low or low certainty evidence. Low certainty evidence suggests that that there may be no benefit with ivermectin for ‘need for mechanical ventilation’, whereas effect estimates for ‘improvement’ and ‘deterioration’ favoured ivermectin use. Severe adverse events were rare and evidence of no difference was assessed as low to very low certainty. Evidence on other secondary outcomes was very low certainty.
Interpretation Low to moderate-certainty evidence suggests reductions in covid-19 deaths and infections may be possible by using ivermectin. Employing ivermectin early on may reduce the number of people progressing to severe disease. The apparent safety and low cost suggest that ivermectin could have an impact on the SARS-CoV-2 pandemic globally." strona osf kropka io/k37ft/

Kolejne duze badanie z Florydy, USA, ktore wykazalo znacznie zmniejszona smiertelnosc przy dawkowaniu Iwermektyny (smiertelnosc 15%) w porownaniu z grupa kontrolna (25%).

"Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19

Results: Univariate analysis showed lower mortality in the ivermectin group (25.2% versus 15.0%, OR 0.52, 95% CI 0.29-0.96, P=.03). Mortality was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%, OR 0.15, CI 0.05-0.47, P=.001), but there was no significant difference in successful extubation rates (36.1% vs 15.4%, OR 3.11 (0.88-11.00), p=.07). After adjustment for between-group differences and mortality risks, the mortality difference remained significant for the entire cohort (OR 0.27, CI 0.09-0.85, p=.03; HR 0.37, CI 0.19-0.71, p=.03). 

Conclusions and Relevance: Ivermectin was associated with lower mortality during treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory support.  
medrxiv kropka org/content/10.1101/2020.06.06.20124461v1  

Jest przelom z iwermektyna, podana podana razem z antybiotykiem doksycyklina (w innych panstwach na swiecie powszechnie podaje sie inny antybiotyk, azytromycyne, ktory jednak jest drozszy i trudniej dostepny).
Tekst po angielsku, wybralem najwazniejsze akapity, publikacja medyczna:

"We have got astounding results. Out of 60 COVID-19 patients, all recovered as the combination of the two drugs were applied, said Professor Dr Md Tarek Alam, the head of medicine department at private Bangladesh Medical College Hospital (BMCH). Alam, a reputed clinician in Bangladesh, said a frequently used antiprotozoal medicine called Ivermectin in a single dose with Doxycycline, an antibiotic, yielded virtually the near-miraculous result in curing the patients with COVID-19. ... Claiming that the efficacy of the drug developed by them was such that patients recovered from the virus within 4 days, he said, adding that there were no side effects of it. ... But all of them have shown remarkable recovery being (COVID-19) negative in four days and 50 per cent reduction of symptoms in 3 days, he said. medicaldialogues kropka in/medicine/news/doxycycline-and-ivermectin-combo-may-be-new-effective-covid-19-treatment-65868?infinitescroll=1